Skip to main content
Premium Trial:

Request an Annual Quote

Applied Proteomics, DKFZ to Collaborate on Cancer MDx

NEW YORK (GenomeWeb News) – Applied Proteomics today said that it will collaborate with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) on the discovery and development of molecular diagnostic tests for colon and pancreatic cancer.

Applied Proteomics President and CEO Peter Klemm said that the firm will leverage its mass spectrometry-based platform in the collaboration. Further terms were not provided by the partners.

San Diego-based Applied Proteomics noted that it is developing a blood-based test for precursors to colorectal cancer aimed at identifying high-risk patients for colonoscopy. The firm recently raised $28 million in a Series C financing round.